Follistatin-344
Follistatin-344 is not a peptide. It is indexed alongside Growth factors and growth hormone-derived compounds because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Growth factors and growth hormone-derived compounds |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Follistatin-344 is the 344-residue isoform of follistatin, a glycoprotein rather than a peptide, and PubChem returned no compound record for the name. A 1987 Proceedings of the National Academy of Sciences paper reports its isolation and partial characterisation as a single-chain monomeric protein, and a 1990 Science paper identifies the activin-binding protein from rat ovary as follistatin.
The retrieved records are developmental and molecular biology. A 1994 Cell paper describes it as an antagonist of activin expressed in the Spemann organizer, a 1995 Nature paper reports multiple defects and perinatal death in follistatin-deficient mice, a 1997 Mechanisms of Development paper reports antagonism of BMP-4, a 1998 Proceedings of the National Academy of Sciences paper reports direct binding to a bone morphogenetic protein and its receptor, and 2002 Journal of Biological Chemistry and 2004 Developmental Biology papers report that it complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis.
[2, 3, 4, 5, 6, 7, 8, 9]Reported mechanism
A glycoprotein that binds and antagonises activin, bone morphogenetic proteins and myostatin, per the retrieved records.
[3, 7, 9]Stated in the titles of the cited 1990 Science, 1998 Proceedings of the National Academy of Sciences and 2004 Developmental Biology papers.
Targets named in the cited records: activin, myostatin, bone morphogenetic proteins.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Follistatin-344 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- follistatin
- FST
- activin-binding protein
Where this page sits
Research records
Cited research records for Follistatin-344, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- ACE-031 — Growth factors and growth hormone-derived compounds
- Mechano growth factor — Growth factors and growth hormone-derived compounds
Class page: Growth factors and growth hormone-derived compounds. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Follistatin-344?
Follistatin-344 is the 344-residue isoform of follistatin, a glycoprotein rather than a peptide, and PubChem returned no compound record for the name. A 1987 Proceedings of the National Academy of Sciences paper reports its isolation and partial characterisation as a single-chain monomeric protein, and a 1990 Science paper identifies the activin-binding protein from rat ovary as follistatin.
Which class is Follistatin-344 indexed under?
Follistatin-344 is indexed under Growth factors and growth hormone-derived compounds. This class groups the growth factors, growth factor fragments and growth hormone-derived proteins that research-peptide catalogues list alongside the secretagogues, most of which are proteins rather than peptides and are labelled as such on their pages.
What does the FDA application register show for Follistatin-344?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:follistatin-344
- Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proceedings of the National Academy of Sciences of the United States of America (1987). pmid:3120188
- Activin-binding protein from rat ovary is follistatin. Science (New York, N.Y.) (1990). pmid:2106159
- Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell (1994). pmid:8168135
- Multiple defects and perinatal death in mice deficient in follistatin. Nature (1995). pmid:7885475
- The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mechanisms of development (1997). pmid:9178255
- Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proceedings of the National Academy of Sciences of the United States of America (1998). pmid:9689081
- The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. The Journal of biological chemistry (2002). pmid:12194980
- Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Developmental biology (2004). pmid:15136138
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.